ANI PHARMACEUTICALS

Company snapshot

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ANI PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ANI PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   ILUVIEN — Approved

2. Jun 8, 2026 Clinical update

   Iluvien 0.19 MG Drug Implant — Approved

3. Jun 8, 2026 Clinical update

   ILUVIEN 0.19 MG — Approved

4. Jun 8, 2026 Clinical update

   Fluocinolone Acetonide — Phase 2

5. Jun 8, 2026 Clinical update

   Fluocinolone Acetonide Intravitreal Implant 0.18 mg — Approved

View all clinical trial activity →

• What is ANI PHARMACEUTICALS?

  ANI Pharmaceuticals is a pharma organization headquartered in Princeton, USA. It trades on NYSE under ticker ANIP. Primary therapeutic focus areas include Diabetic Macular Edema, Non-infectious Uveitis Affecting the Posterior Segment of the Eye, Age-Related Macular Degeneration,

• Is ANI PHARMACEUTICALS publicly traded?

  Yes. ANI PHARMACEUTICALS is listed with ticker ANIP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ANI PHARMACEUTICALS develop or market?

  We link 7 drug profile(s) where ANI PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ani-pharmaceuticals-inc#company-drugs.

• What are the latest developments for ANI PHARMACEUTICALS?

  In the last 12 months our linked public records show 11 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does ANI PHARMACEUTICALS focus on?

  ANI PHARMACEUTICALS focuses on Diabetic Macular Edema, Non-infectious Uveitis Affecting the Posterior Segment of the Eye, Age-Related Macular Degeneration based on our analysis of their pipeline programs and drug development activities.